From Quartz.

🎥 Video Details 🎥

🌟 About This Video 🌟
The FDA issued a warning letter to Novo Nordisk after a Jan. 13–Feb. 7, 2025 inspection found systemic failures in required adverse event reporting. The FDA warning letter detailed cases involving semaglutide, the active ingredient in Ozempic and Wegovy. Inspectors said Novo Nordisk missed 15‑day deadlines and improperly rejected or invalidated reports, conflicting with federal rules. Examples included a death not yet reported, a disabling stroke, and a user’s suicidal thoughts left under review for two months. Procedures allowed reporters to dismiss events as unrelated, and cases were invalidated despite identifiers in source records. The company has 15 business days to outline corrective actions and said the notice does not question safety or quality of its treatments, including semaglutide, liraglutide, nedosiran sodium, and estradiol. #fda #novonordisk #drugsafety #semaglutide #regulatorycompliance

🤖 Crafted with Rizzle AI 🤖

This video was created using Rizzle AI, the ingenious no-edit video creation platform, with industry-leading assets from GettyImages and Soundstripe. Elevate your video content with Rizzle AI: https://app.rizzle.com/create

🔔 If you enjoyed this video, don’t forget to like, share, and subscribe! 🔔